Biotech
Insider and institutional positioning for the week
[SINGAPORE] For the five trading sessions spanning Mar 13 to 19, institutions were net buyers of Singapore stocks, with net institutional inflow of S$365 million. This took the accumulated net inflow ...
Asia’s biotech moment: From regional strength to global impact
Policy reform, new models and cross-border platforms make the region a key driver of biopharma innovation
Human brain cells run new data centres in Singapore, Melbourne
AI is driving a surge in electricity demand, forcing governments and technology companies to search for more efficient computing systems
Nasdaq-listed biotech company Cytek boosts Singapore facility with US$3 million investment
The firm aims to use the site to spearhead growth in Asia-Pacific
AI-powered microalgae hub to anchor Life3 Biotech’s position in sustainable proteins
Facility slated for completion in the fourth quarter of 2026 will house AI-driven bioreactors and a new visitor centre
Singapore’s biotech strategy will benefit from collective, not competitive, thinking
Successful innovation requires a holistic risk-based approach beyond financial, infrastructure and manpower investments
Novartis strikes deal with UK biotech for up to US$1.7 billion
Novartis is on a deal spree this year, including the US$12 billion acquisition of Avidity Biosciences
Forget chasing the next Pfizer: Singapore’s biotech future lies in innovation, not giants
The Republic may not have a major player to call its own, but licensing deals and early-stage breakthroughs can still count as wins
Redefining industries through innovation and insight
These Emerging Enterprise Awards finalists are applying technology and data to make businesses more efficient and improve lives
Novartis agrees to buy Avidity in US$12 billion biotech deal
The full deal is expected to close in the first half of 2026, subject to the completion of the separation
